MedTrace Logo

Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study

NCT00767221 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2009-04-21

No results posted yet for this study

Summary

The study will investigate the effect of PL-56 on albumin leakage and renal function (glomerular filtration rate) in patients with IgA nephropathy. It will also assess the safety of treatment with PL-56.

Conditions

Interventions

DRUG

Budesonide

8 mg PL-56 once daily for six months

Sponsors & Collaborators

  • Archimedes Development Ltd

    collaborator INDUSTRY

  • Calliditas Therapeutics AB

    lead INDUSTRY

Principal Investigators

  • Bengt Fellström, MD, PhD · Uppsala University Hospital, Dept. of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00767221 on ClinicalTrials.gov